FOREWORD Multiple sclerosis therapeutics: opportunities, strategies and challenges

1994). 4. PRISMS Study Group: Randomiseddouble-blind placebo-controlled study of interferon β-1a in relapsing/remittingmultiple sclerosis. PRISMS (Prevention ofRelapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) StudyGroup [see comments]. Lancet 352,1498–1504 (1998).5. Johnson KP, Brooks BR, Cohen JA et al.:Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a Phase IIImulticenter, double-blindplacebo-controlled trial. Neurology 45, 1268–1276 (1995).6. Jacobs LD, Beck RW, Simon JH et al.:Intramuscular interferon β-1a therapy initiated during a first demyelinating eventin multiple sclerosis. CHAMPS StudyGroup. N. Engl. J. Med. 343, 898–904 (2000).7. Filippi M, Rovaris M, Inglese M et al.:Interferon β-1a for brain tissue loss in patients at presentation with syndromessuggestive of multiple sclerosis:a randomised, double-blind,placebo-controlled trial. Lancet 364,1489–1496 (2004).8. Kappos L, Polman CH, Freedman MS et al.:Treatment with interferon β-1b delaysconversion to clinically definite and McDonald MS in patients with clinicallyisolated syndromes. Neurology 67,1242–1249 (2006). 9. Polman CH, O'Connor PW, Havrdova Eet al.: A randomized, placebo-controlledtrial of natalizumab for relapsing multiplesclerosis. N. Engl. J. Med. 354, 899–910(2006). 10. Cofield SS, Cutter GR: Novel designs for clinical trials in multiple sclerosis – anotherexcursion to Sirenum scopuli? Therapy 5(5),613–622 (2008). 11. Comabella M: Pharmacogenomics inmultiple sclerosis: getting the right medicineto the right patient. Therapy 5(5), 623–629 (2008).12. Comabella M, Espejo C, Sastre-Garriga J,Rio J: Research highlights. Therapy 5(5),